1. ZHAW digitalcollection
  2. School of Management and Law
  3. Publikationen
  4. Publikationen School of Management and Law
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLabeit, Alexander Michael-
dc.contributor.authorBriones, Jamaica Roanne-
dc.contributor.authorAminkeng, Folefac-
dc.contributor.authorChai, Jia Hui-
dc.contributor.authorCherGoh, Boon-
dc.contributor.authorGoh, Liuh Ling-
dc.contributor.authorLeong, Khai Pang-
dc.contributor.authorLo, Elaine-
dc.contributor.authorNgiam, Kee Yuan-
dc.contributor.authorTai, E. Shyong-
dc.contributor.authorTan, Karen M. L.-
dc.contributor.authorTan, Doreen Su-Yin-
dc.contributor.authorWinther, Michael David-
dc.contributor.authorYan, Benedict-
dc.contributor.authorZemlyanska, Yaroslava-
dc.contributor.authorWee, Hwee Lin-
dc.date.accessioned2023-12-01T16:07:47Z-
dc.date.available2023-12-01T16:07:47Z-
dc.date.issued2021-
dc.identifier.urihttps://www.pgrn.org/resources/Documents/PGRN%20ProgramBook.pdfde_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/29255-
dc.description.abstractPurpose: Pharmacogenetic (PGx) test involves identification of presence or absence of gene variant(s) toguide individualised therapy. An analysis of the UK Biobank reported that 99.5% of participants have at least one actionable pharmacogenetic variant, with an average of 3.7 actionable pharmacogenetic variants involving an average of 12.2 drugs. As such, PGx panel testing, which allows analysis of multiple genes inone assay, can be potentially more cost-effective than conducting PGx tests individually. Moreover, ancestry differences in the prevalence of PGx allele frequencies mean that non-European health systems should curate a panel tailored to local needs. This study details the process of incorporating both clinical and economic considerations to prioritise gene-drug pairs for cost-effectiveness analyses (CEA). This is done as an initial step in curating a pre-emptive PGx panel test for adults in Singapore, a multi-ethnic Asiancity state. Methods: Clinically important gene-drug pairs were initially determined through literature review and were confirmed by the Clinical Pharmacogenomics Implementation Working Group (CPIWG) at the National University Hospital, comprising an oncologist, endocrinologist, endocrine surgeon, pharmacists and pathologist. These gene-drug pairs were then assessed against a selection framework which involves both clinical and economic criteria. Clinical criteria were (1) high evidence for pharmacogenetic testing, (e.g., consistent recommendations across PGx guidelines) (2) high frequency of gene variant; (3) clinical utility (i.e., will result in a change of patient management), while economic criteria were (4) frequency of drug usage; (5) availability of local and international data to conduct CEA (e.g., odds ratio of gene-drug association in specific ancestry group and local cost of managing adverse drug reactions). Results: The CPIWG shortlisted 25 clinically actionable gene-drug pairs based on literature review and local clinical practice. Of those, ten gene-drug pairs (in no particular order) were prioritised for cost- effectiveness evaluation: (1) HLA-B*58:01–allopurinol, (2) TPMT/NUDT15–azathioprine, (3&4) DPYD–capecitabine/ fluorouracil, (5) HLA-B*15:02– carbamazepine, (6) CYP2C19 clopidogrel, (7&8) CYP2D6– codeine/ tramadol, (9) SLCO1B1–simvastatin; (10) CYP2C9/VKORC1–warfarin. To elaborate on reasons in deprioritising other gene-drug pairs: NUDT15/TPMT–mercaptopurine since it is used in paediatric conditions; UGT1A1–irinotecan dosing recommendations require further discussion and planning; CYP2D6 antidepressants because it is difficult to attribute therapeutic failure as a consequence of carryingthe variant allele, since factors such as non-adherence to treatment or drug-drug interactions may influencetherapeutic outcomes. Lastly, HLA-B*57:01–abacavir, DPYD–tegafur, NUDT15/TPMT–thioguanine and CYP2C19–voriconazole owing to a low volume of prescriptions. Conclusion: The selection framework highlights issues faced in curating PGx panels for implementation. This challenge can be addressed through a systematic approach in prioritising gene-drug pairs for CEA, theresults of which will be used to determine possible inclusion in a pre-emptive PGx panel test.de_CH
dc.language.isoende_CH
dc.publisherPharmacogenomics Global Research Networkde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.titlePrioritisation of clinically actionable gene-drug pairs for cost-effectiveness analysis in Singaporede_CH
dc.typeKonferenz: Sonstigesde_CH
dcterms.typeTextde_CH
zhaw.departementSchool of Management and Lawde_CH
zhaw.organisationalunitWinterthurer Institut für Gesundheitsökonomie (WIG)de_CH
zhaw.conference.detailsPGRN-ASHG 2021 Symposium, online, 18 October 2021de_CH
zhaw.funding.euNode_CH
zhaw.originated.zhawNode_CH
zhaw.pages.end72de_CH
zhaw.pages.start71de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.publication.reviewPeer review (Abstract)de_CH
zhaw.title.proceedingsPGRN-ASHG 2021 Symposium Advancements in Global Pharmacogenomics Through Collaborationsde_CH
zhaw.author.additionalNode_CH
zhaw.display.portraitYesde_CH
Appears in collections:Publikationen School of Management and Law

Files in This Item:
There are no files associated with this item.
Show simple item record
Labeit, A. M., Briones, J. R., Aminkeng, F., Chai, J. H., CherGoh, B., Goh, L. L., Leong, K. P., Lo, E., Ngiam, K. Y., Tai, E. S., Tan, K. M. L., Tan, D. S.-Y., Winther, M. D., Yan, B., Zemlyanska, Y., & Wee, H. L. (2021). Prioritisation of clinically actionable gene-drug pairs for cost-effectiveness analysis in Singapore [Conference presentation]. PGRN-ASHG 2021 Symposium Advancements in Global Pharmacogenomics through Collaborations, 71–72. https://www.pgrn.org/resources/Documents/PGRN%20ProgramBook.pdf
Labeit, A.M. et al. (2021) ‘Prioritisation of clinically actionable gene-drug pairs for cost-effectiveness analysis in Singapore’, in PGRN-ASHG 2021 Symposium Advancements in Global Pharmacogenomics Through Collaborations. Pharmacogenomics Global Research Network, pp. 71–72. Available at: https://www.pgrn.org/resources/Documents/PGRN%20ProgramBook.pdf.
A. M. Labeit et al., “Prioritisation of clinically actionable gene-drug pairs for cost-effectiveness analysis in Singapore,” in PGRN-ASHG 2021 Symposium Advancements in Global Pharmacogenomics Through Collaborations, 2021, pp. 71–72. [Online]. Available: https://www.pgrn.org/resources/Documents/PGRN%20ProgramBook.pdf
LABEIT, Alexander Michael, Jamaica Roanne BRIONES, Folefac AMINKENG, Jia Hui CHAI, Boon CHERGOH, Liuh Ling GOH, Khai Pang LEONG, Elaine LO, Kee Yuan NGIAM, E. Shyong TAI, Karen M. L. TAN, Doreen Su-Yin TAN, Michael David WINTHER, Benedict YAN, Yaroslava ZEMLYANSKA und Hwee Lin WEE, 2021. Prioritisation of clinically actionable gene-drug pairs for cost-effectiveness analysis in Singapore. In: PGRN-ASHG 2021 Symposium Advancements in Global Pharmacogenomics Through Collaborations [online]. Conference presentation. Pharmacogenomics Global Research Network. 2021. S. 71–72. Verfügbar unter: https://www.pgrn.org/resources/Documents/PGRN%20ProgramBook.pdf
Labeit, Alexander Michael, Jamaica Roanne Briones, Folefac Aminkeng, Jia Hui Chai, Boon CherGoh, Liuh Ling Goh, Khai Pang Leong, et al. 2021. “Prioritisation of Clinically Actionable Gene-Drug Pairs for Cost-Effectiveness Analysis in Singapore.” Conference presentation. In PGRN-ASHG 2021 Symposium Advancements in Global Pharmacogenomics through Collaborations, 71–72. Pharmacogenomics Global Research Network. https://www.pgrn.org/resources/Documents/PGRN%20ProgramBook.pdf.
Labeit, Alexander Michael, et al. “Prioritisation of Clinically Actionable Gene-Drug Pairs for Cost-Effectiveness Analysis in Singapore.” PGRN-ASHG 2021 Symposium Advancements in Global Pharmacogenomics through Collaborations, Pharmacogenomics Global Research Network, 2021, pp. 71–72, https://www.pgrn.org/resources/Documents/PGRN%20ProgramBook.pdf.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.